Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...
Net loss for the third quarter of 2024 was $54.4 million, compared to a net loss of $38.6 million for the third quarter of 2023. This included non-cash share-based compensation expense of $8.3 million ...